Proton Pump Inhibitors Use in Patients With Psoriasis

EMS

Status and phase: Withdrawn; Phase 4

Conditions: Psoriasis

Treatments: Drug: esomeprazole; Drug: desonide

Study type: Interventional

Funder types: Industry

Identifiers

NCT02624544

EMS

Details and patient eligibility

About

Proton pump inhibitors act in blocking acid secretion and also have antioxidant and anti-inflammatory properties. For that mechanisms possibly PPIs may have an anti-inflammatory action with improvement in skin lesions in patients with psoriasis.

Full description

Proton pump inhibitors act in blocking acid secretion and also have antioxidant and anti-inflammatory properties. For that mechanisms possibly PPIs may have an anti-inflammatory action with improvement in skin lesions in patients with psoriasis.

The study will assess the evolution of skin lesions in psoriasis patients using PPIs

Sex: All

Ages: 18 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnostic of Psoriasis

Exclusion criteria

• Pregnancy

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

0 participants in 2 patient groups

Group A

Experimental group

Description:

Proton Pump Inhibitor esomeprazole 40 mg twice a day

Treatment:

Drug: esomeprazole

Group B

Active Comparator group

Description:

desonide

Treatment:

Drug: desonide